Anna Bayes
Acute Care · Ashland, KYNPI 1548379175
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by GSK at 26.3% of the total. Among acute care clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$718
- Actelion Pharmaceuticals US, Inc.$700
- Grifols USA, LLC$446
- Novartis$433
- Supernus Pharmaceuticals, Inc.$406
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,01098%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$372
- AIRSUPRA$144
- TEZSPIRE$144
- BREZTRI$144
- FASENRA$144
- CHARTIS CATHETER$126
- ZEPHYR DELIVERY CATHETER$126
- ZEPHYR ENDOBRONCHIAL VALVE$126
- PULMONX CHARTIS TABLET CONSOLE$126
How this compares
$7,185 in reported general payments places this provider in the 95th percentile of 319 acute care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 610 | $494,823 |
| Fasenra PenBenralizumab | 49 | $276,924 |
| NucalaMepolizumab | 60 | $216,239 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $158,510 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 170 | $120,221 |
| Breo ElliptaFluticasone/Vilanterol | 184 | $112,673 |
| Spiriva RespimatTiotropium Bromide | 92 | $73,349 |
| Spiriva HandihalerTiotropium Bromide | 53 | $34,557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 581 | $23,842 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $23,685 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $18,112 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 86 | $16,353 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $13,477 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $13,228 |
| Roflumilast | 185 | $11,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,889 | $854,800926 claims |
| Grifols USA, LLCProlastin C | $446 | $158,51023 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $718 | $147,740254 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $17 | $98,497136 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $31 | $92916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 319 acute care providers in Kentucky.
Other acute care in Ashland
- Brittany ShortAshland$6K
- Candice StevensAshland$5K
- Pamela ParkerAshland$4K
- Caitlin ArthurAshland$2K
- Shannon AtkinsonBowling Green$63K
- Billie WaltersLexington$20K
- Audra MarcumLexington$14K
- Holly ChitwoodLexington$10K
- Vanessa PaddyElizabethtown$8K
- Baylee KnoxGlasgow$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.